To examine if TRAF6 is necessary for the proliferation and survival of LMP1-driven B cell lymphomas, TRAF6 was targeted by an ex vivo CRISPR/Cas9 approach in the two LMP1-dependent B cell lymphomas LMP1-CL 37 and 40 derived from the transgenic CD19-Cre;R26LMP1stopfl:CD3εKO mouse model10,63. Here, TRAF6 is linked to B-cell non-Hodgkin lymphoma.